Kidney Cancer - Xconomy

by in

Entry	Author	Date	Location
Lessons For Drug Development From The Aveo Buzzsaw	Luke Timmerman	05/06/13	National
Aveo Shares Plummet as FDA Advisory Panel Votes Down Cancer Drug	Ben Fidler	05/02/13	Boston
Aveo (Barely) Passes Study With Kidney Cancer Drug, Stock Falls	Luke Timmerman	01/03/12	Boston
Antigenics Expands Experimental Cancer Treatment, Novartis Adds to Cambridge Presence, Boston Scientific Sells Unit to Stryker, & More Boston-Area Life Sciences News	Erin Kutz	10/29/10	Boston
Antigenics, and its UCSF Champion, Stick With Immune Booster For Brain Cancer	Luke Timmerman	10/25/10	Boston
Aveo Pharma Stock Jumps 40 Percent in A Week, CEO Notes Progress in Pivotal Kidney Cancer Trial	Ryan McBride	08/31/10	Boston
Aveo Pharmaceuticals Eyes $86.3M IPO	Ryan McBride	12/17/09	Boston
Antigenics Shares Plummet as Cancer Vaccine Application Rejected in Europe	Luke Timmerman	10/21/09	Boston
Aveo Pieces Together a Plan to Rival Big Boys of Cancer Drug World	Luke Timmerman	06/29/09	Boston
ZymoGenetics Kidney Cancer Drug Shrinks, Stabilizes Tumors in Sickest Patients	Luke Timmerman	05/31/09	Seattle
Aveo Kidney Cancer Drug, Challenging Pfizer and Bayer, Passes Important Test	Luke Timmerman	05/29/09	Boston
ZymoGenetics Takes Back Full Rights to Cancer Drug Candidate	Luke Timmerman	01/28/09	Seattle
Antigenics Asks European Regulators to Approve Oncophage for Kidney Cancer	Luke Timmerman	10/22/08	Boston
Page 1 of 1

Xconomy National